About Cytoki

Cytoki Leadership

Cytoki’s leadership brings together deep expertise in IL-22 biology, lipidation technology, and the discovery and clinical development of novel drugs to address metabolic disease. We are uniquely positioned to leverage the potential of IL-22 as a new treatment paradigm for metabolic diseases, including obesity, and type 2 diabetes, as well as conditions characterized by epithelial injury, such as inflammatory bowel disease (IBD).

Our team

Rasmus Jorgensen, PhD

CEO & Founder

Anne Louise Kjølbye, PhD, MBA

Chief Development Officer

Martijn van de Bunt, MD, DPhil

Chief Scientific Officer

Dorte Waaben, MSc

Head of CMC

Anuj Madhok, PhD

Head of Business Development

Karsten Skydsgaard, DVM, E*MBA

Head of Non-Clinical Development

Christian Friis

Clinical Project Leader

Our board

Christian Elling

Managing Partner, Lundbeckfonden BioCapital

Karen Wagner

Managing Partner, Ysios Capital

Dani Bach

Partner, +ND Capital

Annegret de Baey-Diepolder

Venture Partner, Seventure Partners

Our investors